<DOC>
	<DOCNO>NCT01070030</DOCNO>
	<brief_summary>This study assess efficacy safety combination therapy Aliskiren/Amlodipine Aliskiren/Amlodipine/Hydrochlorothiazide patient stage II Hypertension .</brief_summary>
	<brief_title>Efficacy Safety Combination Therapy Aliskiren/Amlodipine Aliskiren/Amlodipine/Hydrochlorothiazide Patients With Stage II Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Outpatients 18 year age old Male female patient eligible . Female patient must either postmenopausal one year , surgically sterile , use effective contraceptive method oral contraceptive , barrier method spermicidal intrauterine device . Patients diagnosis hypertension follow msDBP &amp; msSBP Requirements : For newly diagnosed/untreated patient : Mean Sitting Diastolic Blood Pressure ( msDBP ) ≥ 100 &lt; 120 mmHg , and/or mean sit Systolic Blood Pressure ( msSBP ) ≥ 160 &lt; 200 mmHg Visit1 . For previously treat patient 1 2 antihypertensive medication : msDBP ≥ 90 &lt; 100 mmHg , and/or msSBP ≥ 140 &lt; 160 mmHg Visit 1 AND msDBP ≥ 100 &lt; 120 mmHg , and/or msSBP ≥ 160 &lt; 200 mmHg Visit 2 . For previously treat patient Atenolol 50 mg daily alone 2 week consecutively visit 1 : msDBP ≥ 100 &lt; 120 mmHg , and/or msSBP ≥ 160 &lt; 200 mmHg . Patients eligible able participate study , consent purpose nature investigation clearly explain ( write inform consent ) . Patients previously participate Aliskiren study . Inability receive completely replace previous antihypertensive medication Atenolol 50 mg daily period 2 week require protocol . Patients 1 ( Atenolol 50 mg daily ) 2 antihypertensive drug msDBP ≥ 100 mmHg and/or msSBP ≥ 160 mmHg Visit 1 . Patients 3 antihypertensive drug Visit 1 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( ≥ 5 mIU/mL ) . Sexually active female patient use effective contraceptive method . Serum potassium &lt; 3.5 mEq/L ( mmol/L ) &gt; 5.5 mEq/L Visit 1 . Second third degree heart block without pacemaker , potentially lifethreatening symptomatic arrhythmia current history . History noncompliance medical regimen unwillingness comply study protocol . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stage II Hypertension , Aliskiren , Amlodipine , Hydrochlorothiazide</keyword>
</DOC>